Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.

被引：0
|
作者：
Franken, Ingrid A.
van der Baan, Frederieke H.
Vink, Geraldine R.
May, Anne Maria
van Grevenstein, Wilhelmina M. U.
Koopman, Miriam
Roodhart, Jeanine
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Utrecht, Netherlands
[3] Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Surg Oncol, Utrecht, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3616
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months
    Franken, Ingrid A.
    van der Baan, Frederieke H.
    Vink, Geraldine R.
    May, Anne M.
    van Grevenstein, Wilhelmina M. U.
    Koopman, Miriam
    Roodhart, Jeanine M. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 208
  • [2] Real-world survival outcomes associated with completion of adjuvant chemotherapy for stage III colon cancer.
    Boyle, Jemma Megan
    Kuryba, Angela
    Cowling, Thomas E.
    van der Meulen, Jan
    Fearnhead, Nicola S.
    Walker, Kate
    Braun, Michael
    Aggarwal, Ajay
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials
    Batra, Atul
    Kong, Shiying
    Cheung, Winson Y.
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : E226 - E234
  • [4] Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and ACHIEVE-2 trials
    Yamanaka, T.
    Yoshino, T.
    Kotaka, M.
    Manaka, D.
    Shiozawa, M.
    Sakamoto, Y.
    Munemoto, Y.
    Eto, T.
    Shitara, K.
    Kato, T.
    Shiomi, A.
    Hasegawa, J.
    Makiyama, A.
    Takagane, A.
    Nakamura, M.
    Oki, E.
    Yamazaki, K.
    Mizushima, T.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    Mori, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S237 - S237
  • [5] The effect of gaps in chemotherapy on survival in patients with high-risk stage II and stage III colon cancer
    Sada, Yvonne
    Duan, Zhigang
    El-Serag, Hashem
    Davila, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [6] Real world survival outcomes in patients with high risk stage II colon cancer at a Beijing Cancer Hospital
    Wu, Aiwen
    Chen, Peng-ju
    Li, Tian-le
    Dankwa-Mullan, Irene
    Sun, Ting-Ting
    Rhee, Kyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Adjuvant Chemotherapy Use and Outcomes of Patients With High-Risk Versus Low-Risk Stage II Colon Cancer
    Kumar, Aalok
    Kennecke, Hagen F.
    Renouf, Daniel J.
    Lim, Howard J.
    Gill, Sharlene
    Woods, Ryan
    Speers, Caroline
    Cheung, Winson Y.
    CANCER, 2015, 121 (04) : 527 - 534
  • [8] REAL-WORLD COSTS OF ADJUVANT TREATMENT FOR STAGE III COLON CANCER PATIENTS IN THE NETHERLANDS
    van Gils, C. W. M.
    Tan, S. S.
    Redekop, W. K.
    Punt, C. J. A.
    VALUE IN HEALTH, 2009, 12 (07) : A267 - A267
  • [9] Clinical Decision Support for High-Risk Stage II Colon Cancer: A Real-World Study of Treatment Concordance and Survival
    Chen, Peng-ju
    Li, Tian-le
    Sun, Ting-ting
    Willis, Van C.
    Roebuck, M. Christopher
    Bravata, Dena M.
    Liu, Xin-zhi
    Arriaga, Yull E.
    Dankwa-Mullan, Irene
    Wu, Ai-wen
    DISEASES OF THE COLON & RECTUM, 2020, 63 (10) : 1383 - 1392
  • [10] Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
    Iveson, Timothy J.
    Sobrero, Alberto F.
    Yoshino, Takayuki
    Souglakos, Ioannis
    Ou, Fang-Shu
    Meyers, Jeffrey P.
    Shi, Qian
    Grothey, Axel
    Saunders, Mark P.
    Labianca, Roberto
    Yamanaka, Takeharu
    Boukovinas, Ioannis
    Hollander, Niels H.
    Galli, Fabio
    Yamazaki, Kentaro
    Georgoulias, Vassilis
    Kerr, Rachel
    Oki, Eiji
    Lonardi, Sara
    Harkin, Andrea
    Rosati, Gerardo
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 631 - +
12345